[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342591-105":59,"doc-detail-342591-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","anlotinib-inhibits-cisplatin-resistance-in-non-small-cell-lung-cancer-cells-by-inhibiting-mcl-1-expression-via-metstat3akt-pathway","Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway","","Anlotinib is investigated for its ability to suppress cisplatin (DDP) resistance in non-small-cell lung cancer (NSCLC) by focusing on MCL-1 regulation through the MET/STAT3/Akt pathway. Cell viability, proliferation, migration, and invasion are assessed using CCK-8, colony formation, and transwell assays, alongside qRT-PCR for MET and MCL-1 transcripts and western blot for pathway markers. Results show anlotinib reduces DDP resistance-associated phenotypes and lowers MET and MCL-1 levels; MET knockdown dampens STAT3/Akt activity and MCL-1 expression, while MET overexpression counteracts these effects. MCL-1 knockdown or STAT3/Akt inhibition abolishes the reversal.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anlotinib-inhibits-cisplatin-resistance-in-non-small-cell-lung-cancer-cells-by-inhibiting-mcl-1-expression-via-metstat3akt-pathway/342591/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anlotinib-inhibits-cisplatin-resistance-in-non-small-cell-lung-cancer-cells-by-inhibiting-mcl-1-expression-via-metstat3akt-pathway/342591.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the central mechanism proposed for anlotinib against cisplatin resistance in NSCLC?","Question",{"text":113,"@type":114},"The study proposes that anlotinib inhibits cisplatin resistance by decreasing MCL-1 expression through the MET/STAT3/Akt pathway.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How are MET, MCL-1, and STAT3/Akt pathway markers evaluated in the experiments?",{"text":118,"@type":114},"MET and MCL-1 mRNA levels are measured by quantitative real-time PCR, while MET, MCL-1, and STAT3/Akt-related protein markers are examined using western blot analysis.",{"name":120,"@type":111,"acceptedAnswer":121},"What happens when MET is silenced or overexpressed in relation to anlotinib’s effects?",{"text":122,"@type":114},"Silencing MET suppresses STAT3/Akt pathway activity and reduces MCL-1 expression, whereas MET overexpression reverses anlotinib’s inhibition of cisplatin resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342591,1790154631,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Hindawi  \nCanadian Respiratory Journal  \nVolume 2024, Article ID 2632014, 12 pages [https://doi.org/10.1155/2024/2632014](https://doi.org/10.1155/2024/2632014)  \nResearch Article  \nAnlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/ Akt Pathway  \nLile Wang , 1,2 Lu Xu , 1,2 Shuhua Han , 1,2 and Xiaoli Zhu 1,2  \n1 Department of Respiratory Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China 2 School of Medicine, Southeast University, Nanjing 210009, China  \nCorrespondence should be addressed to Xiaoli Zhu; [zhuxiaoli62@163.com](zhuxiaoli62@163.com)  \nReceived 5 December 2022; Revised 10 October 2023; Accepted 8 February 2024; Published 4 March 2024  \nAcademic Editor: Jack Kastelik  \nCopyright © 2024 Lile Wang et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nBackground. Anlotinib is an efective targeted therapy for advanced non-small-cell lung cancer (NSCLC) and has been found to mediate chemoresistance in many cancers. However, the underlying molecular mechanism of anlotinib mediates cisplatin (DDP) resistance in NSCLC remains unclear. Methods. Cell viability was assessed by the cell counting kit 8 assay. Cell proliferation, migration, and invasion were determined using the colony formation assay and transwell assay. Te mRNA expression levels of mesenchymal-epithelial transition factor (MET) and myeloid cell leukemia-1 (MCL-1) were measured by quantitative real-time PCR. Protein expression levels of MET, MCL-1, and STAT3/Akt pathway-related markers were examined using western blot analysis. Results. Our data showed that anlotinib inhibited the DDP resistance of NSCLC cells by regulating cell proliferation and metastasis. Moreover, MET and MCL-1 expression could be decreased by anlotinib treatment. Silencing of MET suppressed the activity of the STAT3/Akt pathway and MCL-1 expression. Furthermore, MET overexpression reversed the inhibitory efect of anlotinib on the DDP resistance of NSCLC cells, and this efect could be eliminated by MCL-1 knockdown or ACT001 (an inhibitor for STAT3/Akt pathway) . Conclusion. Our results confrmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.  \n1. Introduction  \nNon-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80% of the total lung cancer [1, 2] . NSCLC is characterized by easy recurrence, micrometastasis, and poor prognosis, so its treatment is very difcult [3, 4] . At present, chemotherapy and molecular targeted therapy are the main treatment methods for NSCLC, but the occurrence of drug resistance is a major problem to be solved in clinical practice [5–7] . Terefore, it is of great signifcance to explore the molecular mechanism of drug resistance for efective treatment of NSCLC.  \nAnlotinib, a novel multitarget tyrosine kinase inhibitor (TKI), has inhibition efects on tumor angiogenesis and growth [8, 9]. In addition to being used as a third-line treatment for patients with advanced NSCLC [10], the  \nantitumor efects ofanlotinib have been found in many other types of cancer, such as oral squamous cell carcinoma [11] and thyroid cancer [12]. Mesenchymal-epithelial transition factor (MET) is a receptor tyrosine kinase that regulates cell proliferation, apoptosis, metastasis, and drug resistance [13]. Some research studies have shown that METis overexpressed in osteosarcoma tumor tissues, and anlotinib suppresses osteosarcoma progression and cisplatin (DDP) resistance by reducing MET expression and phosphorylation [14, 15]. Moreover, anlotinib has been confrmed to decrease MET expression and phosphorylation to hinder colorectal carcinoma cell growth and oxaliplatin resistance [16]. A recent ","cbCaicViid2A7McJ","https://ap.wps.com/l/cbCaicViid2A7McJ","pdf",3003937,12,"English","# Introduction\n# Methods\n## Cell Culture and Treatment\n# Results\n# Discussion","[{\"question\":\"What is the central mechanism proposed for anlotinib against cisplatin resistance in NSCLC?\",\"answer\":\"The study proposes that anlotinib inhibits cisplatin resistance by decreasing MCL-1 expression through the MET/STAT3/Akt pathway.\"},{\"question\":\"How are MET, MCL-1, and STAT3/Akt pathway markers evaluated in the experiments?\",\"answer\":\"MET and MCL-1 mRNA levels are measured by quantitative real-time PCR, while MET, MCL-1, and STAT3/Akt-related protein markers are examined using western blot analysis.\"},{\"question\":\"What happens when MET is silenced or overexpressed in relation to anlotinib’s effects?\",\"answer\":\"Silencing MET suppresses STAT3/Akt pathway activity and reduces MCL-1 expression, whereas MET overexpression reverses anlotinib’s inhibition of cisplatin resistance.\"}]","Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway | PDF",1790047282,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b4db5b5b3bf1949fa866ee4e9a461cf.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4607670b722bd9e203d960b482896cee.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79d75ef5a572044b243e85f269e3ac3b.webp",981,1307,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3f5b00ba4af8c5ac0f43e41a1720efc.webp",980,1306]